Profit Hunter

 Subscriber Feature

Related Views On News
' 185 ' related views found. Displaying results 1 - 10

  • Ranbaxy: Challenges persist
    (May 16, 2014)
    Ranbaxy has announced results for the fifth quarter and 15 months ended March 2014 (The company has changed its accounting year from December to March ending). The company has reported a mere 1% YoY growth in sales and a loss of Rs 736 m for the quarter.
    (Quarterly Results Update)

      
  • Ranbaxy: Quite a poor show
    (Oct 30, 2013)
    Ranbaxy has announced its 3QCY13 results. The company has reported an increase of 3.1% YoY in sales and a loss of Rs 4.5 bn at the net level.
    (Quarterly Results Update)

      
  • Ranbaxy: Forex losses take toll
    (Aug 8, 2013)
    Ranbaxy has announced its 2QCY13 results. The company has reported an 18% YoY drop in sales and a loss of Rs 5.2 bn at the net level.
    (Quarterly Results Update)

      
  • Ranbaxy settles with US regulators
    (May 15, 2013)
    Ranbaxy Laboratories Ltd has announced that the company has concluded the investigation by the US department of Justice (DOJ) for data integrity and manufacturing processes at its two facilities viz., Dewas and Poanta Sahib located in India.
    (Company Info)

      
  • Ranbaxy: Life without 'Lipitor'
    (May 8, 2013)
    Ranbaxy has announced its 1QCY13 results. The company has reported 34% YoY decline in sales and 90% decline at the net level. Here is our analysis of the results.
    (Quarterly Results Update)

      
  • Ranbaxy: The 'Lipitor' impact
    (Feb 26, 2013)
    Ranbaxy has announced its 4QCY12 results. The company has reported 29% YoY decline in sales and a loss of Rs 4.9 bn at the net level. Here is our analysis of the results.
    (Quarterly Results Update)

      
  • Ranbaxy: Lipitor strengthens base business
    (Nov 9, 2012)
    Ranbaxy has announced its 3QCY12 results. The company has reported 31% YoY growth in sales and a 262% YoY increase in net profits. Here is our analysis of the results.
    (Quarterly Results Update)

      
  • Indian pharma: A walk through 'Para IVs'
    (Sep 21, 2012)
    We keep reading about the various patent challenges being filed in US, against various global generic pharma companies.
    (Sector Info)

      
  • Ranbaxy: Buoyed by 'Lipitor' largesse
    (May 10, 2012)
    Ranbaxy has announced its 1QCY12 results. The company has reported 71% YoY and 312% YoY growth in sales and net profits respectively. Here is our analysis of the results.
    (Quarterly Results Update)

      
  • Ranbaxy: Awaiting clarity over Lipitor
    (Nov 22, 2011)
    Ranbaxy has declared third quarter results for calendar year 2011-2012 (3QCY11). The company has reported an 8.7% YoY growth in net sales and a net loss of Rs 4.6 bn this quarter. Here is our analysis of the results.
    (Quarterly Results Update)

      
     Subscriber Feature
      Next 10>>   Next 20>>
    RANBAXY LAB STOCK QUOTE
    BSE: 597.75 (0.11%)
    NSE: 597.50 (0.22%)
    Oct 23, 2014 (Close)
    View Detailed Quote

    TRACK RANBAXY LAB
    • Track your investment in RANBAXY LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    MORE ON RANBAXY LAB

    RANBAXY LAB - TEVA PHARMA COMPARISON
    Compare Company With Charts

    COMPARE RANBAXY LAB WITH
     

    OTHER USEFUL LINKS

    MARKET STATS
     
    Pharma
     

     
       Go